Key Takeaways
MacroGenics Inc. agreed to sell its primary drug manufacturing operations to Bora Pharmaceuticals for $122.5 million in cash, a move that provides non-dilutive funding for its cancer-therapy pipeline and sent its shares up over 2 percent.
"This transaction supports that strategy by providing additional non-dilutive capital to accelerate our pipeline to key value inflection points in 2026 and beyond,” Eric Risser, President and Chief Executive Officer of MacroGenics, said in a statement.
The deal transfers MacroGenics’ good manufacturing practice (GMP) facilities in Rockville and Frederick, Maryland, to Bora. The Rockville site includes an FDA-approved facility with 11,000 liters of total capacity. Approximately 140 MacroGenics employees are expected to join Bora.
The sale, expected to close in the third quarter of 2026, allows MacroGenics to focus on its core business of developing antibody-based cancer therapeutics. The company will retain access to the facilities through a supply agreement with Bora to support its development pipeline.
The transaction is a key part of Bora’s strategy to expand its biologics contract development and manufacturing (CDMO) operations in North America, according to company Chairman Bobby Sheng. For MacroGenics, the deal follows a pattern of non-dilutive financing to strengthen its balance sheet and extend its cash runway, which it previously guided into late 2027.
On May 4, the company announced an expanded royalty sale for its ZYNYZ drug, which brought in a $60 million upfront payment. The stock (NASDAQ: MGNX) gained 2.04% to close at $3.00 on the day of the manufacturing sale announcement.
Analysts have a median price target of $7.50 on MacroGenics, with B. Riley Securities holding a $9.00 target and Barclays at $6.00.
The infusion of $122.5 million strengthens MacroGenics' balance sheet without diluting shareholders, allowing the company to focus resources on advancing its clinical-stage oncology assets. Investors will watch for progress on the pipeline candidates and the successful integration of the manufacturing operations by Bora, which is expected in Q3 2026.
This article is for informational purposes only and does not constitute investment advice.
